In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for ...

Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the ...

Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...

The general mood among these heavyweight investors is divided, with 35% leaning bullish and 37% bearish. Among these notable options, 12 are puts, totaling $1,065,123, and 33 are calls, amounting to ...

In the last week of December, while most of the U.S. was still in holiday mode, Novo Nordisk’s plant in North Carolina was ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...

Novo Nordisk's Wegovy pill is now available, providing those seeking help with their weight a GLP-1 medicine in a pill for ...

In December, the FDA approved the once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. Manufacturing ...

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore ...